Edition:
United States

Johnson & Johnson (JNJ)

JNJ on New York Consolidated

111.94USD
5 Dec 2016
Change (% chg)

$-0.02 (-0.02%)
Prev Close
$111.96
Open
$112.40
Day's High
$112.42
Day's Low
$111.73
Volume
5,427,339
Avg. Vol
6,739,392
52-wk High
$126.07
52-wk Low
$94.28

JNJ

Chart for JNJ

About

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. The Company's segments include Consumer, Pharmaceutical and Medical Devices. The Consumer segment includes a range of products used in the baby care, oral care, skin care,... (more)

Overall

Beta: 0.74
Market Cap(Mil.): $312,861.19
Shares Outstanding(Mil.): 2,720.53
Dividend: 0.80
Yield (%): 2.78

Financials

  JNJ Industry Sector
P/E (TTM): 20.16 29.13 29.87
EPS (TTM): 5.71 -- --
ROI: 14.16 15.56 14.95
ROE: 22.09 16.69 16.29

Actelion's silence has hedge funds betting big on J&J deal

ZURICH Actelion's silence speaks volumes to the dozens of event-driven hedge funds piling into the Swiss biotech firm, betting that Johnson & Johnson's (J&J) approach will result in an outright takeover and handsome returns.

Dec 02 2016

Johnson & Johnson hit with over $1 billion verdict on hip implants

A federal jury in Dallas on Thursday ordered Johnson & Johnson and its DePuy Orthopaedics unit to pay more than $1 billion to six plaintiffs who said they were injured by Pinnacle hip implants.

Dec 01 2016

Actelion shares fall on report it rejects J&J offer

ZURICH Shares in Swiss biotech company Actelion fell more than 6 percent after news outlet streetinsider.com reported on Wednesday the company had rejected a full takeover offer by U.S. healthcare group Johnson & Johnson and may sell a unit.

Nov 30 2016

Rejecting J&J could leave Actelion with 'lot of explaining to do'

ZURICH/LONDON Some Actelion shareholders would be attracted by a $27 billion bid for the Swiss biotech company from Johnson & Johnson, leaving Chief Executive Jean-Paul Clozel with some explaining to do if he turned down an offer around that level.

Nov 30 2016

Deals of the day-Mergers and acquisitions

Nov 29 The following bids, mergers, acquisitions and disposals were reported by 2100 GMT on Tuesday:

Nov 29 2016

J&J raises Actelion takeover pressure with higher price: source

LONDON U.S. healthcare company Johnson & Johnson has raised its offer for Actelion, a source told Reuters on Tuesday, stepping up pressure on the Swiss biotech firm to accept a takeover deal.

Nov 29 2016

Actelion shares plunge on report it eyes 'complicated' J&J deal

ZURICH Shares in Swiss biotech company Actelion plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a "complicated deal" to link with U.S. healthcare giant Johnson & Johnson .

Nov 29 2016

Actelion shares plunge on report it eyes "complicated" J&J deal

ZURICH, Nov 29 Shares in Swiss biotech company Actelion plunged on Tuesday after a report the company was not actively considering selling itself, but instead weighing a "complicated deal" to link with U.S. healthcare giant Johnson & Johnson.

Nov 29 2016

PRESS DIGEST- Financial Times - Nov 29

Nov 29 The following are the top stories in the Financial Times. Reuters has not verified these stories and does not vouch for their accuracy.

Nov 28 2016

Actelion's ambitious independent-minded CEO will drive up takeover price

ZURICH Actelion Chief Executive Jean-Paul Clozel's desire to keep Europe's biggest biotech company independent after building it from scratch, means Johnson & Johnson will have to pay a steep premium if a takeover is to succeed.

Nov 28 2016

Earnings vs. Estimates